12:02 AM EDT, 06/24/2026 (MT Newswires) -- AlphaValue/Baader Europe cut its EPS estimates for Genmab (GMAB.CO), expecting higher net financial expenses from the Merus deal to "significantly" impact the Danish biotechnology company's bottom line. "The firm raised $5.5bn to fund the Merus acquisition, which is expected to be accretive to EBITDA, with projected annual sales of at least $1bn by 2029 and a substantial contribution thereafter. This has led to increased interest expenses. Additionally, the firm utilised its entire $1.6bn in marketable securities to finance the acquisition, resulting in a loss of interest and investment income. Consequently, our projections for net financial income of $99.6m in 2026 and $95.6m in 2027 have been revised to net financial expenses of $350m and $325m, respectively," analysts said Tuesday. The EPS forecasts were therefore reduced by 27.2% to $14 for 2026 and 17% to $18.2 for 2027. "Despite significant revisions in estimates, as detailed in the EPS section, Genmab's long-term prospects remain robust," the research firm noted, citing upcoming data readouts and product launches. The stock is rated buy, with a price target of 2,693 Danish kroner.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.